Sermorelin: Research overview, identity, and laboratory handling guide

Synthetic 29-residue GHRH(1-29) analogue widely studied in vitro for GHRH-receptor binding research. ≥99% HPLC. Research use only. This guide covers identity, published research context, procurement checks, and storage — RUO only, no clinical claims.

What Sermorelin is in published research

Sermorelin is the 29-residue N-terminal fragment of native GHRH and is the minimum sequence reported in the literature to retain full GHRH-receptor activity. Research labs use sermorelin as a parent reference standard against modified GHRH analogues (CJC-1295, Tesamorelin) in receptor-binding, cAMP, and cell-line signaling assays.

Each lot ships with ≥99% HPLC purity and MS identity verification covering the full 29-residue sequence and the C-terminal amide. Net peptide content is reported on the CoA. Sermorelin is a useful reference standard for SAR work; we can supply matched-lot sermorelin alongside CJC-1295 (No DAC) for direct comparison studies.

Hold lyophilized vials sealed at -20 °C protected from light. Sermorelin is sensitive to oxidation at Met-27; reconstitute with bacteriostatic water and aliquot before freezing. Avoid prolonged storage of reconstituted material above 8 °C.

CoA covers identity (MS), purity (HPLC), Met-oxidation summary where in scope, and net peptide content. Batch records by lot are filed against the SKU.

The material class "GHRH(1-29) analogue (research)" helps procurement teams group Sermorelin with related reference peptides during comparative studies.

Sequence and identity

Sermorelin identity on the catalog: Common name: Sermorelin (GRF 1-29); Sequence: H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2; Length: 29 residues; Molecular formula: C149H246N44O42S; Molecular weight: 3,357.88 g/mol; Appearance: White lyophilized powder; Purity (HPLC): ≥ 99%; Net peptide: Listed on CoA; Solubility: Soluble in bacteriostatic water. Copy these into receiving and LIMS before reconstitution.

Mechanisms studied in published research

Mechanism-focused research on Sermorelin is typically conducted in cell lines or biochemical preparations that express the relevant receptor or binding protein for its class.

Design controls that include scrambled-sequence or orthogonal-receptor negative controls when your protocol evaluates Sermorelin pharmacology in vitro.

Report effect sizes with lot number and CoA reference so results can be reproduced if the same Sermorelin SKU is reordered later.

Avoid extrapolating in vitro binding or signaling readouts to whole-organism outcomes; RUO materials are not qualified for clinical investigation.

Procurement and identity verification

Request the lot-specific CoA for Sermorelin at receipt. Verify SKU, variant size if applicable, and identity mass before the lot enters general storage.

Compare HPLC purity to your internal minimum for the peptide family. File chromatogram excerpts when your QMS requires raw data.

Enter net peptide content from the CoA into inventory before calculating molarity for Sermorelin working stocks.

Attach purchase order, packing list, and CoA in one audit folder per lot.

Storage and reconstitution

Store lyophilized Sermorelin sealed at -20 °C protected from light unless the CoA states otherwise.

Reconstitute with bacteriostatic water or a buffer validated for your assay pH. Aliquot to limit freeze-thaw.

For oxidation-sensitive sequences in Sermorelin, minimize open-vial time at room temperature during weighing.

See our lyophilized storage guide for institution-scale SOP examples and aliquot labeling conventions.

Comparative reference points

Researchers comparing Sermorelin with adjacent catalog references often evaluate the following SKUs in parallel plates:

Use matched reconstitution buffers and stock concentrations when running comparative binding or signaling assays.